FY2025 EPS Estimates for Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Reduced by Leerink Partnrs

Aldeyra Therapeutics, Inc (NASDAQ:ALDXFree Report) – Analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Aldeyra Therapeutics in a research report issued on Tuesday, July 9th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post earnings per share of $0.50 for the year, down from their prior estimate of $0.55. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.23) per share.

Aldeyra Therapeutics (NASDAQ:ALDXGet Free Report) last announced its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06).

A number of other equities analysts have also commented on ALDX. Oppenheimer restated an “outperform” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Monday, May 6th. StockNews.com lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Monday, May 6th.

Check Out Our Latest Stock Analysis on Aldeyra Therapeutics

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ ALDX opened at $3.40 on Thursday. The firm has a market cap of $201.99 million, a P/E ratio of -6.67 and a beta of 1.45. Aldeyra Therapeutics has a 1-year low of $1.42 and a 1-year high of $8.38. The business’s 50 day moving average is $3.73 and its 200-day moving average is $3.58.

Hedge Funds Weigh In On Aldeyra Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its stake in shares of Aldeyra Therapeutics by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 3,446 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Aldeyra Therapeutics by 23.4% in the 1st quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 4,797 shares during the last quarter. Prime Capital Investment Advisors LLC bought a new position in shares of Aldeyra Therapeutics in the 4th quarter valued at $35,000. Woodstock Corp increased its stake in shares of Aldeyra Therapeutics by 5.9% in the 2nd quarter. Woodstock Corp now owns 180,806 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 10,091 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Aldeyra Therapeutics in the 4th quarter valued at $39,000. Institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

(Get Free Report)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.

See Also

Earnings History and Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.